Oncology

Eric von Hofe, PhD, president and chief operating officer of AffyImmune, discussed advantages of the Affinity tuning platform.

Jan Davidson, MD, PhD, chief medical officer, Wugen, discussed the company’s future plans and research.

The professor and director of the Myeloma Center at the University of Arkansas for Medical Sciences discussed the clinical implications of CAR T-cell therapy for patients with relapsed/refractory multiple myeloma.

Oncternal and Celularity hope to produce ROR1-targeted NK, CAR-NK, and CAR T-cell therapies.

The chief executive and medical officers of Cytovia Therapeutics discussed the company's therapeutic targets and cell therapy scaffold.

The CAR T-cell therapy elicited an overall response rate (ORR) of 97.9% at a median follow-up of 18 months.

Patients with CDI also had more severe acute graft vs. host disease than those without CDI.

The hematologist and oncologist from the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center discussed unmet needs with CAR T-cell therapy in multiple myeloma.

The hematologist and oncologist from University of California, San Francisco discussed the current state of cellular therapy in multiple myeloma.

The new technologies were made available as a result of the licensing agreement between MD Anderson and Bellicum Pharmaceuticals.

The associate professor from the Harold C. Simmons Comprehensive Cancer Center of UT Southwestern Medical Center discussed the latest data from the KarMMA trial.

The director of the Solid Tumor Immunotherapy Lab at the University of Pennsylvania discussed his research into the mechanisms of the BET protein family and T cells.

Paul Rennert, president and chief scientific officer of Aleta BioTherapeutics, discussed the company’s research on CAR T therapies.

A phase 1/2a clinical trial assessing VOR33 is currently enrolling.

The chief executive and chief medical officers of Celyad Oncology discussed the company’s future research and plans.

Jan Davidson, MD, PhD, chief medical officer, Wugen, discussed the company’s cell therapy platforms.

The associate professor from The University of Texas MD Anderson Cancer Center discussed the integration of CAR T-cell therapy into the treatment paradigm of R/R MM.

The hematologist and oncologist from City of Hope discussed the utility of CAR T cells in patients with hematologic cancers.

Paul Lammers, MD, MSc, president and chief executive officer, Triumvira Immunologics, discussed the company’s T-cell antigen coupler technology.

A new TIL therapy seeks to improve on current treatments for metastatic non-small cell lung cancer such as PD-1 inhibitors.

The director of the Solid Tumor Immunotherapy Lab at the University of Pennsylvania discussed the issue of exhausted T-cells.

The chief executive and medical officers of Cytovia Therapeutics discussed their natural killer cell therapy technology.

Michael Singer, MD, PhD, chief scientific officer, Cartesian Therapeutics, discussed the company’s RNA Armory technology.

The professor and director of the myeloma center at the University of Arkansas for Medical Sciences discussed future research with CAR T in multiple myeloma.

Adoptive transfer of TILs elicited an ORR of 56% in patients with metastatic melanoma who were naïve to PD-1 inhibitors compared with 24% in patients refractory to PD-1 inhibitors.

Paul Rennert, president and chief scientific officer of Aleta BioTherapeutics, discussed the company’s CAR T Engager protein technology.

Six of 7 mice treated with a new, higher dose of BMN-307 showed tumors in liver necropsy at 52 weeks post-treatment.

The hematologist/oncologist at the Harold C. Simmons Comprehensive Cancer Center discussed the rationale behind using CAR T-cell therapy in relapsed/refractory multiple myeloma and data from the KarMMa trial.

Jennifer Buell, PhD, president and chief operating officer of Agenus, discussed cell therapy for multiple myeloma and COVID-19 respiratory distress.

Experts discussed novel options such as CAR T-cell therapy for optimizing treatment in MCL, myelofibrosis, and ALL.